74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
FibroGen Inc
Closed
SectorHealthcare
0.31 3.33
Overview
Share price change
24h
Min
0.3
Max
0.31
Income | 35M 18M |
|---|---|
Sales | -170M -123M |
EPS | -0.08 |
Profit margin | -14.589 |
Employees | 225 |
EBITDA | -74M -91M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +3125.81% upside |
Next Earnings | 5 May 2025 |
|---|
Market Cap | -16M 29M |
|---|---|
Previous open | -3.02 |
Previous close | 0.31 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
FibroGen Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
FibroGen Inc Forecast
Price Target
By TipRanks
3125.81% upside
12 Months Forecast
Average 10 USD 3125.81%
High 10 USD
Low 10 USD
Based on 2 Wall Street analysts offering 12 month price targets forFibroGen Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
